Format

Send to

Choose Destination
Mol Cell Oncol. 2019 Mar 20;6(3):1571984. doi: 10.1080/23723556.2019.1571984. eCollection 2019.

Targeting HER2 beyond breast cancer.

Author information

1
Department of Biochemistry and Molecular Genetics, University of Virginia Cancer Center, Charlottesville, VA, USA.
2
Laboratory of Novel Biologics, Department of Biochemistry and Molecular Genetics, University of Virginia Cancer Center, Charlottesville, VA, USA.

Abstract

The structural basis of blocking human epidermal growth factor receptor-2 (HER2) dimerization remains of great interest to generate effective anti-cancer therapies. Despite clinically feasible outcome in mammary tumors, a fine consensus between efficacy and safety remains a critical challenge beyond breast cancer. Here we extrapolate on the balancing act using recently reported clinical findings in salivary ductal carcinomas.

KEYWORDS:

Targeted therapies; cancer; immunotherapy

PMID:
31131305
PMCID:
PMC6512921
[Available on 2020-03-20]
DOI:
10.1080/23723556.2019.1571984

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center